RayzeBio, Inc. Common Stock
RayzeBio, Inc. Common Stock (RYZB) Net Income & Profit History
Annual & trailing net income, net margin, YoY change, and peer profitability context.
RYZB · net income · updated Jun 9, 2026
Core profitability metrics
RYZB · net income · margin · TTM · CAGRNet income was −$68.6M for FY2022 (fiscal year ending 2022-12-31), down 133.0% year-over-year. Net profit margin was —.
Annual net income history
▸ FMP /income-statement · Annual · RYZB net income history · RYZB profit margin
Annual net income data
Net income vs peers (Healthcare)
About Net Income & Methodology
RayzeBio, Inc. Common Stock (RYZB) reported net income of −$68.6M for FY2022 (fiscal year ending 2022-12-31), down 133.0% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.
RayzeBio, Inc. Common Stock has not yet achieved annual profitability based on available data (3 fiscal years). The company has reported net losses across all available periods.
RayzeBio, Inc. Common Stock's net profit margin was — for FY2022, based on the latest annual results.
Investors sometimes search for "RayzeBio, Inc. Common Stock net worth" — the company's market capitalization is a separate figure from RYZB net income. Data sourced from FMP /income-statement · US GAAP · USD.
Frequently asked questions
RYZB net income · 4 questionsRayzeBio, Inc. Common Stock is not currently profitable on an annual basis. The company reported a net loss of $68.6M for FY2022.
▸ Source: FMP /income-statement · GAAP · RayzeBio, Inc. Common Stock · RayzeBio, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026